Bond.az White LogoBond.az Black Logo

#biomarin

Latest news and interesting information about biomarin.

2026-05-22 11:53
|
473

BioMarin Neutral Rating, $50 Target by HC Wainwright

H.C. Wainwright reiterates Neutral on BioMarin with $50 target after Phase 3 hypochondroplasia results. Stock at $54.10, competitive landscape analyzed.

0
2026-05-20 20:44
|
462

BioMarin stock surges on positive hypochondroplasia trial data

BioMarin stock jumped 4.8% after positive Phase 3 trial results for VOXZOGO in hypochondroplasia, showing significant growth improvements.

0
2026-05-20 19:01
|
686

Biotech at Inflection Point: JPMorgan Covers 14 Firms | Bond.az

JPMorgan covers 14 biotech firms at inflection point, with ratings and price targets. See which companies are poised for growth and the catalysts ahead.

0
...